Transcript Britain Stirs Outcry by Weighing Benefits of Drugs Versus

The Use of Cost-Effectiveness
Information in Coverage Policy
Decisions in the U.S. and the
U.K.
Stirling Bryan Ph.D.
University of Birmingham, U.K.
University of British Columbia, Canada
Britain Stirs Outcry by Weighing
Benefits of Drugs Versus Price
Millions of patients around the world have taken
drugs introduced over the past decade to delay
the worsening of Alzheimer's disease. …
But this year, an arm of Britain's government
health-care system, relying on some economists'
number-crunching, said the benefit isn't worth the
cost. It issued a preliminary ruling calling on
doctors to stop prescribing the drugs.
THE WALL STREET JOURNAL November 22, 2005; Page A1